Bolt Biotherapeutics (NASDAQ:BOLT) Releases Earnings Results, Misses Estimates By $0.04 EPS

Bolt Biotherapeutics (NASDAQ:BOLT) announced its quarterly earnings data on Tuesday. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.04), Zacks reports. The business had revenue of $1.14 million for the quarter, compared to the consensus estimate of $1.02 million. Bolt Biotherapeutics had a negative return on equity of 64.49% and a negative net margin of 665.56%.

Bolt Biotherapeutics Stock Down 2.8 %

NASDAQ:BOLT traded down $0.02 during mid-day trading on Wednesday, hitting $0.62. 56,758 shares of the company’s stock were exchanged, compared to its average volume of 165,355. The company has a quick ratio of 4.28, a current ratio of 4.28 and a debt-to-equity ratio of 0.19. Bolt Biotherapeutics has a fifty-two week low of $0.55 and a fifty-two week high of $1.56. The company has a 50 day simple moving average of $0.64 and a 200-day simple moving average of $0.74.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “neutral” rating on shares of Bolt Biotherapeutics in a research report on Wednesday. Five analysts have rated the stock with a hold rating, According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $3.50.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.